These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8733410)

  • 1. Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection.
    Elliott AM; Foster SD
    Tuber Lung Dis; 1996 Feb; 77(1):27-9. PubMed ID: 8733410
    [No Abstract]   [Full Text] [Related]  

  • 2. Rebuttal: time to call a halt to emotions in the assessment of thioacetazone.
    Rieder HL; Enarson DA
    Tuber Lung Dis; 1996 Apr; 77(2):109-11. PubMed ID: 8762843
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya.
    van Gorkom J; Kibuga DK
    Tuber Lung Dis; 1996 Feb; 77(1):30-6. PubMed ID: 8733411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further consequences of thioacetazone-induced cutaneous reactions.
    Lawn SD; Griffin GE
    Int J Tuberc Lung Dis; 2000 Jan; 4(1):92-3. PubMed ID: 10654652
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of thiacetazone.
    Foster S; Kelly P
    Lancet; 1995 Jan; 345(8941):62-3. PubMed ID: 7528311
    [No Abstract]   [Full Text] [Related]  

  • 6. Wrong drug used for tuberculosis.
    Kelly PM
    Int J Tuberc Lung Dis; 1997 Aug; 1(4):385. PubMed ID: 9432398
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
    Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Life-threatening cutaneous reactions to thiacetazone-containing antituberculosis treatment in Kumasi, Ghana.
    Lawn SD; Frimpong EH; Acheampong JW
    West Afr J Med; 1999; 18(4):249-53. PubMed ID: 10734785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya.
    Hawken M; Nunn P; Gathua S; Brindle R; Godfrey-Faussett P; Githui W; Odhiambo J; Batchelor B; Gilks C; Morris J
    Lancet; 1993 Aug; 342(8867):332-7. PubMed ID: 7687729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of thiacetazone.
    Wilkinson D; Moore D
    Lancet; 1995 Jan; 345(8941):63. PubMed ID: 7528313
    [No Abstract]   [Full Text] [Related]  

  • 11. Cutaneous reactions to thiacetazone in Zambia--implications for tuberculosis treatment strategies.
    Kelly P; Buve A; Foster SD; McKenna M; Donnelly M; Sipatunyana G
    Trans R Soc Trop Med Hyg; 1994; 88(1):113-5. PubMed ID: 7512287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of tuberculosis in developing countries.
    Pozniak A
    Lancet; 1995 Oct; 346(8982):1099. PubMed ID: 7564806
    [No Abstract]   [Full Text] [Related]  

  • 13. Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma.
    Watkins WM; Mungai M; Muhia DK; Mberu EK; Gathua S; Winstanley PA; Gilks CF; Nunn P
    Br J Clin Pharmacol; 1996 Feb; 41(2):160-2. PubMed ID: 8838444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of thiacetazone.
    Fegan D
    Lancet; 1995 Jan; 345(8941):63. PubMed ID: 7528312
    [No Abstract]   [Full Text] [Related]  

  • 15. [Skin toxicity of thiacetazone (TB1) at a hospital service in Dakar].
    Dieng MT; Ndiaye B; Camara C
    Dakar Med; 2001; 46(1):1-3. PubMed ID: 15773145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiacetazone toxicity in the treatment of tuberculosis patients in Nigeria.
    Pearson CA
    J Trop Med Hyg; 1978 Dec; 81(12):238-42. PubMed ID: 85717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe hypersensitivity reactions among HIV-seropositive patients with tuberculosis treated with thioacetazone.
    Wkly Epidemiol Rec; 1992 Jan; 67(1-2):1-3. PubMed ID: 1371055
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cutaneous reactions to thiacetazone (TB1) (author's transl)].
    Strobel M; Ndiaye B; Marchand JP; Jovet JC
    Rev Fr Mal Respir; 1979; 7(5):467-70. PubMed ID: 95055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I.
    Chintu C; Luo C; Bhat G; Raviglione M; DuPont H; Zumla A
    Arch Dis Child; 1993 May; 68(5):665-8. PubMed ID: 7686737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse cutaneous reactions to thiacetazone for tuberculosis treatment in Tanzania.
    Ipuge YA; Rieder HL; Enarson DA
    Lancet; 1995 Sep; 346(8976):657-60. PubMed ID: 7544858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.